Revita type II diabetes treatment launches in London

Chloe Kent 28 January 2020 (Last Updated January 28th, 2020 13:10)

A minimally invasive endoscopic procedure to treat type II diabetes is now available to self-paying patients at London’s Princess Grace Hospital.

Revita type II diabetes treatment launches in London
Revita works by using hydrothermal ablation technology to deliver treatment to a part of the upper intestine called the duodenum. Credit: Shutterstock

A minimally invasive endoscopic procedure to treat type II diabetes is now available to self-paying patients at London’s Princess Grace Hospital.

Known as Revita, the procedure can enhance insulin sensitivity, lower HbA1c and create long-term improvements in blood sugar control to avoid further medication escalation. This is the first time the treatment has ever been commercially available.

Princess Grace Hospital consultant gastroenterologist Dr Bu Hayee said: “The arrival of Revita will offer new hope to these patients that the symptoms of the disease can be reversed. Patients can go home the same day, following treatment, with minimal side effects – it really is a unique option.”

The Revita diabetes treatment works by using hydrothermal ablation technology to deliver treatment to a part of the upper intestine called the duodenum. The outer lining of the duodenum is treated to make way for new, healthy cells to regenerate, enabling better use of the body’s own natural insulin.

The procedure is intended for type II diabetics already on daily oral medications, whose bodies are still able to produce their own insulin but whose condition is escalating. It can be completed in an hour, after which patients can return home.

Revita clinical trial patient Russell Pearson said: “Before my Revita procedure I was taking two diabetes tablets and my GP was concerned I might have to take insulin in the future. After Revita my blood sugar improved for the first time in years and I have also reduced my daily medication. My recent blood test shows my levels are now better than the pre-diabetic range.”

Revita has undergone a series of global clinical trials involving almost 300 patients. The research published to date shows that those who undergo the procedure generally have improved overall insulin sensitivity, HbA1c lowered by nearly 1%, moderate weight loss, reduction in liver fat and increased HDL cholesterol.

Coupled with a continued healthy diet and exercise, a single Revita diabetes treatment can last for up to two years. While many patients with type II diabetes attempt to control their blood glucose levels with lifestyle changes, these can sometimes be ineffective and they end up facing daily insulin injections.